Results 161 to 170 of about 343,340 (395)
Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes
BreastBackground: Dose-dense sequential (dds) chemotherapy has changed the clinical outcome of patients with early breast cancer (BC). To investigate the impact of dose intensity (DI) in the adjuvant setting of BC, this observational trial (HE 10/10) was ...Foteinos-Ioannis Dimitrakopoulos, Anna Goussia, Georgia-Angeliki Koliou, Katerina Dadouli, Anna Batistatou, Helen P. Kourea, Mattheos Bobos, Petroula Arapantoni-Dadioti, Olympia Tzaida, Triantafyllia Koletsa, Sofia Chrisafi, Maria Sotiropoulou, Alexandra Papoudou-Bai, Irene Nicolaou, Antonia Charchanti, Davide Mauri, Gerasimos Aravantinos, Ioannis Binas, Eleni Res, Amanda Psyrri, Dimitrios Pectasides, Dimitrios Bafaloukos, Anna Koumarianou, Iliada Bompolaki, Georgios Rigakos, Charisios Karanikiotis, Angelos Koutras, Flora Zagouri, Helen Gogas, George Fountzilas +29 moredoaj +1 more sourceSupplementary Tables S1 and S2 from Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma
, 2023 Maria Vassilakopoulou, Margaritis Avgeris, Vamsidhar Velcheti, Vassiliki Kotoula, Theodore Rampias, Kyriakos Chatzopoulos, Christos Perisanidis, Christos K. Kontos, Aris Ι. Giotakis, Andreas Scorilas, David L. Rimm, Clarence T. Sasaki, George Fountzilas, Amanda Psyrri +13 moreopenalex +1 more sourcePre‐Encoded IFN‐I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors
Advanced Science, EarlyView.Type I interferon (IFN‐I) signaling promotes p21‐dependent cell cycle arrest in senescent tumor‐specific memory T cells, resulting in poor proliferative responses and solid tumor regression during cancer vaccination. Conversely, IFNα/β receptor blockade reinvigorates T cell proliferation to regress solid tumors and is more effective with increasing ...Andrew Nguyen, Scott R Walsh, Li Deng, Lan Chen, Yonghong Wan +4 morewiley +1 more sourceT Cell Glycoengineering to Modulate Immune‐Tumor Crosstalk: A Universal Non‐Genetic Strategy for Enhanced Tumor Immunotherapy
Advanced Science, EarlyView.This study describes a T cell surface engineering strategy that integrates polymer materials with tumor immunology, aiming to achieve broad‐spectrum anti‐tumor applications of glycopolymer‐engineered T (G‐T) cells via non‐genetic modification. Glycopolymer engineering generally modulates immune‐tumor crosstalk through specific cell‐cell interactions ...Lihua Yao, He Yang, Fangjian Shan, Xiaomeng Niu, Yichen Wang, Hengyuan Zhang, Sujian Wang, Gaojian Chen, Hong Chen +8 morewiley +1 more sourceFAPα+ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD‐L1 and T Cell Senescence
Advanced Science, EarlyView.ABSTRACT
Multiple myeloma (MM) is a hematologic malignancy driven by clonal expansion of malignant plasma cells. Despite the long‐term disease control achieved with immunotherapies in some patients, treatment resistance remains a major cause of disease relapse.Huiyao Gu, Zhenfeng Dai, Xi Huang, Enfan Zhang, Xinyuan Dai, Haoguang Chen, Wen Cao, Jinna Zhang, Yifan Hou, Haimeng Yan, Yang Yang, Li Yang, Yi Li, Wenlong Lin, Zhen Cai, Jingsong He +15 morewiley +1 more sourceThe evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
Annals of Oncology, 2015 Roberto Salgado, Roberto Salgado, C. Denkert, S. Demaria, N. Sirtaine, F. Klauschen, G. Pruneri, S. Wienert, G. V. D. Eynden, F. Baehner, F. Penault-Llorca, E. A. Perez, E. Thompson, W. Symmans, A. Richardson, J. Brock, C. Criscitiello, H. Bailey, M. Ignatiadis, G. Floris, J. Sparano, Z. Kos, T. Nielsen, D. Rimm, K. Allison, J. Reis-Filho, S. Loibl, C. Sotiriou, G. Viale, S. Badve, S. Adams, K. Willard-Gallo, S. Loi +32 moresemanticscholar +1 more sourceInteractions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy
Advanced Science, EarlyView.Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Marcus M Cheng, Maria F. Camargo, Robert Saddawi‐Konefka, Kanika Dhawan, Ashwyn K. Sharma, Mahsa Mortaja, Sophie Bice, Daniel J. Scanderbeg, Diego Alvarado, Jyoti Mayadev, Ramez N. Eskander, Stephen R. Adams, Pippa F. Cosper, J. Silvio Gutkind, Sunil J. Advani +17 morewiley +1 more sourceThe association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis
EClinicalMedicine, 2021 Feng Li, Caichen Li, Xiuyu Cai, Zhan-hong Xie, Liquan Zhou, B. Cheng, R. Zhong, S. Xiong, Jianfu Li, Zhuxing Chen, Ziwen Yu, Jianxing He, W. Liang +12 moresemanticscholar +1 more source
